Vietnam is rapidly emerging as one of Southeast Asia's most promising genomics markets as healthcare providers, research institutions and biotechnology companies expand investment in Next-Generation Sequencing (NGS). Once confined primarily to academic research, NGS is now playing an increasingly important role in cancer diagnostics, inherited disease testing, infectious disease surveillance and personalised medicine.
Although there is currently no dedicated published valuation for Vietnam's NGS market, industry analysis indicates the sector is worth an estimated US$55–70 million in 2025 and could grow to US$125–160 million by 2030. Growth is being driven by falling sequencing costs, increasing adoption of genomic medicine and expanding government and private sector investment in life sciences.
Next-Generation Sequencing has transformed genomics by enabling millions of DNA or RNA fragments to be analysed simultaneously. Compared with traditional sequencing technologies, NGS provides faster turnaround times, lower costs per genome and significantly greater analytical capability, making it a cornerstone technology for modern healthcare and biomedical research.
The market encompasses a wide range of products and applications, including:
- Whole genome sequencing
- Whole exome sequencing
- Targeted gene panels
- Oncology companion diagnostics
- Reproductive and prenatal screening
- Rare disease diagnostics
- Infectious disease surveillance
- Pharmacogenomics
- Population genomics
- Bioinformatics and genomic data analysis
Vietnam's healthcare system is increasingly embracing precision medicine. Hospitals are expanding genomic testing for cancer patients, while research institutes are investing in sequencing technologies to better understand hereditary diseases and infectious pathogens. The country's growing biotechnology ecosystem is also encouraging wider adoption of NGS across drug discovery, translational research and biomarker development.
Cancer diagnostics remain one of the strongest growth areas. NGS enables clinicians to identify actionable genetic mutations, helping select targeted therapies and monitor disease progression more accurately. As cancer incidence continues to rise across Southeast Asia, demand for comprehensive genomic profiling is expected to increase significantly.
Vietnam is also becoming an important centre for reproductive genetics. Non-invasive prenatal testing (NIPT), carrier screening and newborn genomic testing are increasingly being adopted by private healthcare providers, creating further demand for high-throughput sequencing platforms and advanced laboratory services.
The country's growing genomics ecosystem is illustrated by the expansion of local companies such as Gene Solutions, which has developed genomic testing platforms for oncology, reproductive health and multi-cancer early detection while collaborating with hospitals throughout Southeast Asia. These developments highlight Vietnam's increasing capability in clinical genomics and precision medicine.
Artificial intelligence is further accelerating the value of NGS. Modern sequencing workflows increasingly combine high-throughput sequencing with AI-powered bioinformatics, enabling laboratories to analyse vast genomic datasets more quickly and accurately. As sequencing becomes more accessible, bioinformatics platforms and cloud-based genomic analysis are becoming essential components of precision healthcare.
The broader regional market is experiencing exceptional growth. According to Market Data Forecast, the Asia-Pacific Next-Generation Sequencing Market was valued at US$1.97 billion in 2025 and is projected to grow at a 25.35% CAGR through 2034, supported by expanding government genomics programmes, precision medicine initiatives and biotechnology investment across the region.
Globally, the outlook is equally strong. IMARC Group estimates the Global Next-Generation Sequencing Market reached US$27.0 billion in 2025 and will expand to US$92.8 billion by 2034, reflecting a 14.29% CAGR. Growth is being fuelled by advances in oncology, rare disease diagnosis, infectious disease surveillance, agricultural genomics and pharmaceutical research.
Leading companies operating in the global NGS market include Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, PacBio, Roche, QIAGEN, Agilent Technologies, BGI Genomics, MGI Tech, Danaher (Beckman Coulter Life Sciences) and 10x Genomics. These companies continue to invest heavily in faster sequencing platforms, automation, AI-powered bioinformatics and clinical diagnostic applications.
As Vietnam continues to invest in precision medicine, molecular diagnostics and life sciences research, Next-Generation Sequencing is expected to become a foundational technology across healthcare, pharmaceutical development and biomedical innovation. For sequencing technology providers, laboratory equipment manufacturers, reagent suppliers, bioinformatics companies, pharmaceutical organisations and research institutions, Vietnam represents one of Southeast Asia's fastest-growing genomics markets.